Opsin Biotherapeutics

Opsin Biotherapeutics occupies a specialized position at the intersection of gene therapy, optogenetics, and chronic-pain neuromodulation. Its stated approach is to use opsin-based gene therapy to make pain-blocking neurons responsive to light, with LED or low-power laser activation intended to modulate activity in the spine. The company also describes a non-viral delivery approach and functionalized gold nanorods as part of its technology. These features distinguish its concept from broad pharmacological pain management and from electrical spinal cord stimulation, both of which are identified as relevant treatment alternatives rather than named competitors. Opsin has reported grant support, including $2.35 million from the National Institute of Neurological Disorders and Stroke on Oct 1, 2026, but no commercial product, clinical-stage status, or market adoption data is provided. Its competitive position therefore remains that of an early, research-led therapeutic developer pursuing a differentiated modality, with clinical validation and delivery feasibility central to assessing its future standing.

Founded in 2019, Opsin Biotherapeutics has developed around a focused research proposition: using light-sensitive opsins to modulate pain-blocking neurons. Its funding history shows an early non-equity assistance award associated with MassChallenge on Jul 7, 2021, a $327,864 grant dated Jul 27, 2023, and a $2.35 million grant from the National Institute of Neurological Disorders and Stroke on Oct 1, 2026. The latest award is the clearest reported inflection point in the company’s financing history and raises its recorded total funding to $2,677,864. A patent publication dated Feb 20, 2024 concerning optogenetic modulation of the central nervous system for pain provides another sign of technical development. The company is listed in the 1–10 employee range, with one current position identified: CEO and co-founder Robert Benkowski, who has held the role since 2018. No hiring announcement, product launch, clinical milestone, or partnership is reported.